| Nov 13 |
Q3 2024 Legend Biotech Corp Earnings Call
|
| Nov 13 |
TRex Bio raises $84M to compete in crowded immune drug field
|
| Nov 12 |
J&J sues HHS over 340B hospital drug-discount program
|
| Nov 12 |
J&J Sues U.S. Over Hospital Drug-Discounting Program
|
| Nov 12 |
J&J’s Ottava surgical robot to begin clinical trial after FDA nod
|
| Nov 11 |
J&J gets FDA breakthrough therapy status for nipocalimab in Sjogren's
|
| Nov 11 |
Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren's disease
|
| Nov 11 |
Spravato is just the beginning in a new wave of depression meds
|
| Nov 8 |
Why Johnson & Johnson (JNJ)’s Legal Issues Could Wrap Up Quickly
|
| Nov 8 |
J&J seeks approval of Darzalex for early-stage multiple myeloma
|
